NCT-06128551

Phase 1b, Multicenter, Open-label, Dose Escalation and Dose Expansion Study of RMC-6291 in Combination with RMC-6236 in Participants with Advanced KRASG12C-Mutated Solid Tumors

This is a Phase 1b study taking place at various locations. They're testing varying doses of a drug called RMC-6291 alongside RMC-6236 in individuals with advanced solid tumors that have a specific KRASG12C mutation.

KRASG12C: A KRAS mutation is a specific type of alteration in the KRAS gene, which is part of the RAS gene family. These mutations can lead to uncontrolled cell growth and are commonly found in various cancers, impacting treatment outcomes and guiding therapeutic strategies.

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT06128551

Clinical Trial Site: Columbia

To see all available clinical trials click here.